=== PAGE 5 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

Cells via Distinct Drug Combination Strategies. Clin Cancer Res 2014; 20(9): 2363-74.
6. Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a Potent Inhibitor of FLT3 with Activity Against Resistance-
   Conferring Point Mutants. Blood 2014; 123(1): 94-100.
7. Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3
   Inhibitors. Leukemia 2015; 29(12): 2390-2.


[A large background image of several modern glass high-rise buildings in an urban setting is present. The buildings have many windows, reflecting the sky and surrounding environment. Text is overlaid on this image:]

For more information visit clinicaltrials.gov or contact us directly.

5420 LBJ Freeway, Suite 410
Dallas, TX 75240
Email: info@arogpharma.com

[Below the contact information, there is a circular button with an upward-pointing arrow and the word "TOP" written below it. This button is centered horizontally.]
